Results 41 to 50 of about 17,128 (260)

Nutrition and Metabolic Diseases: A Systematic Review of Functional Foods, Medicinal Plants, Phytochemicals, Bioactive Compounds and Nutrients Effective Against Metabolic Diseases

Food Chemistry International, EarlyView.
The study demonstrates how functional foods, medicinal plants, phytochemicals, bioactive compounds and essential nutrients combat metabolic diseases. It highlights their mechanisms, including antioxidant, anti‐inflammatory, insulin‐sensitising, lipid‐regulating, gut microbiota‐modulating and mitochondrial‐enhancing effects, leading to improved ...
Chinaza Godswill Awuchi, Sana Noreen, Sonia Morya   +2 more
wiley   +1 more source

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression [PDF]

Clinical and Molecular Hepatology
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH.
Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo   +19 more
doaj   +1 more source

Surgically confirmed severe endometriosis is associated with lower risk of steatotic liver disease: Evidence of estrogen‐linked hepatic–reproductive crosstalk

International Journal of Gynecology &Obstetrics, EarlyView.
Severe surgically confirmed endometriosis was associated with a lower prevalence of steatotic liver disease than non‐severe disease. Higher estradiol levels may partly explain this inverse hepatic–reproductive association, supporting integrated gynecologic and hepatologic risk assessment.
Jung Hyun Park, Keungmo Yang, Hyun Yang, Si Hyun Bae, Mee‐Ran Kim, Jaejun Lee   +5 more
wiley   +1 more source

Redefining Fatty Liver Disease: How Updated Nomenclature Reshapes Clinical Laboratory Diagnostics

iLABMED, EarlyView.
The transition from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction‐associated steatotic liver disease (MASLD) reorients laboratory diagnosis from exclusion‐based rules toward metabolic and inflammatory biomarkers. This review compares their diagnostic criteria, epidemiology, insulin resistance mechanisms, imaging, and key laboratory ...
Ran Wei, Yuanyue Guan, Meiqing Zhai, Xiuying Zhao   +3 more
wiley   +1 more source

Fructose induces metabolic reprogramming in liver cancer cells, promoting aggressiveness and chemotherapy resistance [PDF]

Exploration of Digestive Diseases
Aim: Fructose is a highly lipogenic compound related to the onset of steatosis, its progression to steatohepatitis, and the eventual initiation of hepatocellular carcinoma (HCC).
Lisette Chávez-Rodríguez, Alejandro Escobedo-Calvario, Verena Jendrossek, Johann Matschke, Maike Busch, Nicole Dünker, Moisés Vergara-Mendoza, Verónica Souza-Arroyo, Leticia Bucio-Ortiz, Roxana U. Miranda-Labra, Araceli Páez-Arenas, María Concepción Gutiérrez-Ruiz, Diego F. Calvisi, Luis E. Gomez-Quiroz   +13 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Downregulation of the p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation [PDF]

Clinical and Molecular Hepatology
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic. The disease has a strong genetic component, and a common missense variant (rs2642438) in the mitochondrial amidoxime-reducing component 1 (MARC1) gene ...
Ester Ciociola, Tanmoy Dutta, Kavitha Sasidharan, Lohitesh Kovooru, Francesca R. Noto, Grazia Pennisi, Salvatore Petta, Angela Mirarchi, Samantha Maurotti, Bernardette Scopacasa, Luca Tirinato, Patrizio Candeloro, Marcus Henricsson, Daniel Lindén, Oveis Jamialahmadi, Arturo Pujia, Rosellina M. Mancina, Stefano Romeo   +17 more
doaj   +1 more source

Non‐Nutritive Artificial Sweeteners Aspartame and Acesulfame‐K Ameliorate Metabolic Dysfunction‐Associated Steatotic Liver Disease in Male Ldlr−/− Mice

iNew Medicine, EarlyView.
ABSTRACT Aspartame and acesulfame‐K are commonly used non‐nutritive artificial sweeteners, but their impacts on cardiovascular disease and metabolic dysfunction‐associated fatty liver disease (MASLD) are unclear. In this study, we evaluated the impacts of aspartame and acesulfame‐K on MASLD and atherosclerosis in male Ldlr−/− mice fed an AMLN diet ...
Jingjing Xu, Xiaohua Jiang, Jianping Weng, Suowen Xu   +3 more
wiley   +1 more source

Aerobic Exercise as a Therapeutic Strategy in Children and Adolescents with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Obesity: A Systematic Review

Archives of Pediatric Gastroenterology, Hepatology, and Nutrition
Background: Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disease in children and adolescents, particularly those with obesity. MASLD often progresses to serious hepatic and metabolic complications.
Nerissa Arviana Fuad, Annisa Alifianti, Nabila Annisa Harum, William Cheng   +3 more
doaj   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source